Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a magnet lift mood in Parkinson's? new trial aims to find out

NCT ID NCT07569133

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This study tests whether a non-invasive magnetic brain stimulation technique, called rTMS, can help ease depression in people with Parkinson's disease. Fifty adults with mild to moderate depression will be randomly assigned to receive either real rTMS or a sham (fake) treatment for five days. Researchers will measure changes in mood and also use digital tools like facial expression analysis to track results.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
repetitive transcranial magnetic stimulation (rTMS)
What this could lead to
If it works, this could offer a non-drug option to improve mood in people with Parkinson's disease.
What could go wrong
This is a small, early exploratory study with only 50 participants. The sham control uses a tilted coil, which may not be a perfect placebo. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Willing and able to provide written informed consent * Male or female aged 40 to 90 years * Diagnosed with Parkinson's disease with depressive symptoms * Hoehn and Yahr stage 1 to 3 * On stable Parkinson's disease medication for at least 3 months prior to screening, with no planned dose increase during the study period * BDI-II score ≥ 14 (mild depression) or ≥ 20 (moderate depression) * Able to read and write Korean and capable of independently completing questionnaires Exclusion Criteria: * History of epilepsy * Parkinson's disease caused by cerebrovascular disease, CNS infection, intoxication, or traumatic brain injury * Diagnosed with Parkinson-plus syndromes (multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies etc.) * Clinically significant abnormal laboratory values (AST, ALT, or total bilirubin \> 2.5 x ULN) * Diagnosed with psychiatric disorders * Unable to follow instructions or communicate * Pregnant, breastfeeding, or women of childbearing potential * Febrile patients * Patients with artificial hip joint implants * Presence of conductive, ferromagnetic, or magnetically sensitive metal near the head or treatment coil (e.g., cochlear implants, implanted electrodes/stimulators, aneurysm clips or coils) * Cardiac disease, especially patients with pacemakers * Corrected or uncorrected visual acuity less than 0.5 * Use of drug infusion pumps or hearing aids * Patients with acute illness * Patients taking tricyclic antidepressants, neuroleptics, or other medications that may lower seizure threshold * History of increased intracranial pressure or head trauma * Evidence of external wounds on brain or neck * Prominent psychotic symptoms other than depression (high NPI scores for hallucinations, delusions, mania) * History of schizophrenia, bipolar disorder, or substance abuse * Suicidal ideation (BDI-II item 9 score of 2 or 3) * History of or planned deep brain stimulation or stereotactic surgery (pallidotomy, thalamotomy) * Any participant deemed ineligible by the investigator, including those with medical conditions that may increase risk or interfere with study evaluation * Currently enrolled in another clinical trial or used investigational drug/device within 30 days or 5 half-lives prior to consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depression are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depression depressive disorder Nerve Degeneration Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kyungpook National University Chilgok Hospital

    Daegu, Buk-gu, 41404, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.